secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2026-09-23T20:17:30+00:00
Accession:  0001104659-26-109979
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance completes $17/share cash-plus-CVR merger with Zymeworks; delists from Nasdaq
--------------------------------------------------------------------------------

- Merger closed Sept 23, 2026: each TBPH share converted to $17.00 cash plus one contingent value right (CVR).
- CVR pays 80% of net ampreloxetine license proceeds within 10 years, $50M milestone on first US/UK/Spain/France/Germany/Italy sale, and 10% of net sales.
- CEO Rick Winningham and all six directors resigned at closing; Kristin Stafford, Scott Platshon, Paul Schneider appointed as new directors.
- Ordinary shares delisted from Nasdaq; Form 25 to be filed with deregistration via Form 15 planned.
- Merger financed by Zymeworks through cash on hand plus new debt financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926109979/0001104659-26-109979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465926109979/tm2625984d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-109979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer